Denali Therapeutics Inc.
COMPOUNDS, COMPOSITIONS, AND METHODS
Last updated:
Abstract:
The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, isotopically enriched analog, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or pharmaceutical composition thereof, and methods of making and using thereof.
Status:
Application
Type:
Utility
Filling date:
10 Apr 2020
Issue date:
14 Jul 2022